Tivicay patents expiration

TIVICAY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(6 years from now)

Tivicay is owned by Viiv Hlthcare.

Tivicay contains Dolutegravir Sodium.

Tivicay has a total of 2 drug patents out of which 0 drug patents have expired.

Tivicay was authorised for market use on 12 August, 2013.

Tivicay is available in tablet;oral dosage forms.

The generics of Tivicay are possible to be released after 08 December, 2029.

Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient

Market Authorisation Date: 12 August, 2013

Treatment: NA


How can I launch a generic of TIVICAY before it's drug patent expiration?
More Information on Dosage

TIVICAY family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic